Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Should You Buy?

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $3.08, but opened at $3.24. Autolus Therapeutics shares last traded at $3.07, with a volume of 285,730 shares trading hands.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Redburn Atlantic upgraded Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 target price on the stock in a research note on Friday. Needham & Company LLC reissued a "buy" rating and issued a $9.00 price target on shares of Autolus Therapeutics in a report on Monday, November 11th. Finally, The Goldman Sachs Group upgraded Autolus Therapeutics from a "neutral" rating to a "buy" rating and increased their price objective for the company from $7.00 to $7.60 in a research report on Monday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Autolus Therapeutics has an average rating of "Buy" and an average price target of $10.15.

Autolus Therapeutics Stock Performance

The firm has a market capitalization of $795.62 million, a P/E ratio of -2.47 and a beta of 2.04. The business's fifty day moving average price is $3.88 and its two-hundred day moving average price is $3.98.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.10). During the same period in the previous year, the business earned ($0.26) earnings per share. Sell-side analysts predict that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of AUTL. ProShare Advisors LLC purchased a new position in shares of Autolus Therapeutics during the 2nd quarter valued at approximately $43,000. Capstone Investment Advisors LLC purchased a new position in Autolus Therapeutics in the third quarter valued at $51,000. Daiwa Securities Group Inc. raised its position in shares of Autolus Therapeutics by 2,659.7% in the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company's stock worth $55,000 after acquiring an additional 15,293 shares during the period. Herbst Group LLC purchased a new stake in shares of Autolus Therapeutics during the 3rd quarter worth about $91,000. Finally, Bayesian Capital Management LP acquired a new stake in shares of Autolus Therapeutics during the 1st quarter valued at about $100,000. 72.83% of the stock is owned by institutional investors and hedge funds.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.